%A Liu Xiaoling, Li Wenhui, Chang Li, Xia Yaoxiong %T Adjuvant endocrine therapy for breast cancer %0 Journal Article %D 2016 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673422X.2016.03.013 %P 210-212 %V 43 %N 3 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9912.shtml} %8 2016-03-08 %X Endocrinotherapy is an important treatment approach for patients with hormone receptor-positive breast cancer. Tamoxifen, anastrozole and ovarian function inhibitors are the most common drugs in breast cancer endocrinotherapy. However, the choices of endocrinotherapy drugs are different on the basis of the differences in disease stages and menopausal status. Endocrinotherapy has been proved to have good effects, meanwhile, also been shown to can produce drug resistance, mTOR inhibitors, CDK4/6 inhibitors and fibroblast growth factor receptor inhibitors will bring new hope for patients with drug resistance to endocrinotherapy.